Staats HF - Search Results

1

Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity.

Phua KK, Staats HF, Leong KW, Nair SK. Phua KK, et al. Among authors: staats hf. Sci Rep. 2014 Jun 4;4:5128. doi: 10.1038/srep05128. Sci Rep. 2014. PMID: 24894817 Free PMC article.

2

Mast cell-derived particles deliver peripheral signals to remote lymph nodes.

Kunder CA, St John AL, Li G, Leong KW, Berwin B, Staats HF, Abraham SN. Kunder CA, et al. Among authors: staats hf. J Exp Med. 2009 Oct 26;206(11):2455-67. doi: 10.1084/jem.20090805. Epub 2009 Oct 5. J Exp Med. 2009. PMID: 19808250 Free PMC article.

3

Polymer hydrogels: Chaperoning vaccines.

Staats HF, Leong KW. Staats HF, et al. Nat Mater. 2010 Jul;9(7):537-8. doi: 10.1038/nmat2788. Nat Mater. 2010. PMID: 20571480 No abstract available.

4

Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes.

St John AL, Chan CY, Staats HF, Leong KW, Abraham SN. St John AL, et al. Among authors: staats hf. Nat Mater. 2012 Jan 22;11(3):250-7. doi: 10.1038/nmat3222. Nat Mater. 2012. PMID: 22266469 Free PMC article.

5

Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity.

Phua KK, Staats HF, Nair SK, Leong KW. Phua KK, et al. Among authors: staats hf. J Control Release. 2015 Sep 10;213:e66-7. doi: 10.1016/j.jconrel.2015.05.110. Epub 2015 Aug 19. J Control Release. 2015. PMID: 27005208 No abstract available.

6

Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo.

Porgador A, Staats HF, Faiola B, Gilboa E, Palker TJ. Porgador A, et al. Among authors: staats hf. J Immunol. 1997 Jan 15;158(2):834-41. J Immunol. 1997. PMID: 8993001

7

In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity.

Staats HF, Alam SM, Scearce RM, Kirwan SM, Zhang JX, Gwinn WM, Haynes BF. Staats HF, et al. Infect Immun. 2007 Nov;75(11):5443-52. doi: 10.1128/IAI.00529-07. Epub 2007 Aug 20. Infect Immun. 2007. PMID: 17709410 Free PMC article.

8

Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.

Gwinn WM, Kirwan SM, Wang SH, Ashcraft KA, Sparks NL, Doil CR, Tlusty TG, Casey LS, Hollingshead SK, Briles DE, Dondero RS, Hickey AJ, Foster WM, Staats HF. Gwinn WM, et al. Among authors: staats hf. Vaccine. 2010 Oct 4;28(42):6901-14. doi: 10.1016/j.vaccine.2010.08.006. Epub 2010 Aug 17. Vaccine. 2010. PMID: 20723629 Free PMC article.

9

Cytokines: the future of intranasal vaccine adjuvants.

Thompson AL, Staats HF. Thompson AL, et al. Among authors: staats hf. Clin Dev Immunol. 2011;2011:289597. doi: 10.1155/2011/289597. Epub 2011 Jul 31. Clin Dev Immunol. 2011. PMID: 21826181 Free PMC article. Review.

10

Maximal adjuvant activity of nasally delivered IL-1α requires adjuvant-responsive CD11c(+) cells and does not correlate with adjuvant-induced in vivo cytokine production.

Thompson AL, Johnson BT, Sempowski GD, Gunn MD, Hou B, DeFranco AL, Staats HF. Thompson AL, et al. Among authors: staats hf. J Immunol. 2012 Mar 15;188(6):2834-46. doi: 10.4049/jimmunol.1100254. Epub 2012 Feb 15. J Immunol. 2012. PMID: 22345651 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

106 results

Search Page